erlotinib has been researched along with thiopental sodium in 5 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (thiopental sodium) | Trials (thiopental sodium) | Recent Studies (post-2010) (thiopental sodium) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 55 | 0 | 52 |
| Protein | Taxonomy | erlotinib (IC50) | thiopental sodium (IC50) |
|---|---|---|---|
| NUAK family SNF1-like kinase 1 | Homo sapiens (human) | 0.025 | |
| Tyrosine-protein kinase ABL1 | Mus musculus (house mouse) | 9.69 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.2356 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.044 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.044 | |
| Dipeptidyl peptidase 1 | Homo sapiens (human) | 2.1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.044 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.99 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
| Chen, ZS; Korlipara, V; Lei, Z; Romu, AA; Zhou, B | 1 |
| Hou, W; Ma, Y; Ren, Y; Sun, H; Yan, B; Zhang, Z | 1 |
| An, B; Chen, C; Fan, R; Li, J; Li, X; Song, X; Wei, S; Zhang, Q; Zou, Y | 1 |
5 other study(ies) available for erlotinib and thiopental sodium
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
Topics: Acrylamides; Animals; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Mice; Mutagenesis, Site-Directed; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2017 |
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |